Add to ORKGIn this thesis, I investigate the trend of prices of the innovative anticancer drugs approved by the FDA from 1996 to 2016. I focus specifically on firms’ long term pricing strategy in response to the market competition. I also study on the firms’ behavior of introducing newer versions as a way to combat generic entry (Duggan and Morton 2006). Using the data on the market list prices from January 1996 to March 2016 on different versions of anticancer drugs, I find that after generic entry, the price of newer version drugs rise significantly faster than the average rise of prices of drugs when first introduced. This study is the first attempt in the economics literature to describe the pricing trend of anticancer drugs
This paper analyses the behaviour of drug firms facing the threat of having their drugs excluded fro...
When patented, brand-name antibiotics lose market exclusivity, generics typically enter the market a...
When a new firm enters a market and starts selling a spatially-differentiated product, the prices of...
In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab— brand na...
Since generics and biosimilars have entered the Russian market of medications, there are new trends ...
A fundamental question in industrial organization regards the relationship between price and the num...
Empirical studies suggest that entry of generic competitors results in minimal decreases or even inc...
Background: Cancer drugs are a major component of pharmaceutical spending in the USA and Europe. The...
Abstract Background In the United States (U.S.), large price increases for selected generic drugs ha...
BackgroundSome experts have proposed combating rising drug prices by promoting brand-brand competiti...
This paper examines the price effects of generic drugs that are produced by brand-name drug firms an...
Analysis of new anticancer drugs licensed in the UK found that 44 new therapies were approved from 2...
The aim of this paper is to analyse empirically entry decisions by generic firms into markets with t...
A letter report issued by the Government Accountability Office with an abstract that begins "The gro...
abstract: This paper develops a theoretical price competition model, based on the model established ...
This paper analyses the behaviour of drug firms facing the threat of having their drugs excluded fro...
When patented, brand-name antibiotics lose market exclusivity, generics typically enter the market a...
When a new firm enters a market and starts selling a spatially-differentiated product, the prices of...
In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab— brand na...
Since generics and biosimilars have entered the Russian market of medications, there are new trends ...
A fundamental question in industrial organization regards the relationship between price and the num...
Empirical studies suggest that entry of generic competitors results in minimal decreases or even inc...
Background: Cancer drugs are a major component of pharmaceutical spending in the USA and Europe. The...
Abstract Background In the United States (U.S.), large price increases for selected generic drugs ha...
BackgroundSome experts have proposed combating rising drug prices by promoting brand-brand competiti...
This paper examines the price effects of generic drugs that are produced by brand-name drug firms an...
Analysis of new anticancer drugs licensed in the UK found that 44 new therapies were approved from 2...
The aim of this paper is to analyse empirically entry decisions by generic firms into markets with t...
A letter report issued by the Government Accountability Office with an abstract that begins "The gro...
abstract: This paper develops a theoretical price competition model, based on the model established ...
This paper analyses the behaviour of drug firms facing the threat of having their drugs excluded fro...
When patented, brand-name antibiotics lose market exclusivity, generics typically enter the market a...
When a new firm enters a market and starts selling a spatially-differentiated product, the prices of...